MBX Biosciences reported net income of -$37.71M for the quarter ended Jun 2026. This income statement covers 12 quarters of results from Sep 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 1.25M | 1.02M | 1.29M | 1.32M | 6.52M | 10.64M | 33.42M | 33.59M | 34.20M | 36.51M | 47.57M | 47.95M |
| Operating items | ||||||||||||
| Research & DevelopmentR&D | 9.07M | 7.73M | 11.05M | 14.40M | 16.75M | 15.22M | 22.41M | 17.72M | 19.27M | 19.76M | 18.47M | 30.98M |
| Selling, General & AdministrativeSG&A | 1.87M | 2.26M | 2.27M | 2.26M | 2.87M | 3.39M | 4.12M | 4.08M | 4.66M | 6.04M | 8.79M | 9.95M |
| Operating ExpensesOpex | 10.95M | 9.99M | 13.31M | 16.66M | 19.61M | 18.61M | 26.53M | 21.80M | 23.93M | 25.80M | 27.27M | 40.93M |
| Operating IncomeOp. Inc | -10.95M | -9.99M | -13.31M | -16.66M | -19.61M | -18.61M | -26.53M | -21.80M | -23.93M | -25.80M | -27.27M | -40.93M |
| EBIT | -10.95M | -9.99M | -13.31M | -16.66M | -19.61M | -18.61M | -26.53M | -21.80M | -23.93M | -25.80M | -27.27M | -40.93M |
| Non-operating items | ||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.78M | 1.15M | 0.98M | 0.80M | 1.47M | 3.02M | 2.65M | 2.39M | 2.31M | 3.73M | 3.75M | 3.84M |
| Net income details | ||||||||||||
| EBT | -10.16M | -8.84M | -12.34M | -15.86M | -18.14M | -15.59M | -23.88M | -19.41M | -21.62M | -22.06M | -23.52M | -37.09M |
| Profit After TaxPAT | -10.16M | -8.88M | -12.34M | -15.86M | -18.14M | -15.59M | -23.88M | -19.45M | -21.62M | -22.09M | -23.52M | -37.71M |
| Income from Continuing OperationsIncome (Continuing) | -10.16M | -8.84M | -12.34M | -15.86M | -18.14M | -15.59M | -23.88M | -19.41M | -21.62M | -22.06M | -23.52M | -37.09M |
| Consolidated Net IncomeConsol Net Inc. | -10.16M | -8.84M | -12.34M | -15.86M | -18.14M | -15.59M | -23.88M | -19.41M | -21.62M | -22.06M | -23.52M | -37.09M |
| Income towards Parent CompanyParent Net Inc | -10.16M | -8.84M | -12.34M | -15.86M | -18.14M | -15.59M | -23.88M | -19.41M | -21.62M | -22.06M | -23.52M | -37.09M |
| Net Income towards Common StockholdersNet Income | -10.16M | -8.84M | -12.34M | -15.86M | -18.14M | -15.59M | -23.88M | -19.41M | -21.62M | -22.06M | -23.52M | -37.09M |
| Additional items | ||||||||||||
| EPS (Basic) | -9.40 | -8.68 | -10.26 | -12.62 | -2.78 | -1.46 | -0.71 | -0.58 | -0.63 | -0.60 | -0.50 | -0.78 |
| EPS (Diluted) | -9.40 | -8.68 | -10.26 | -12.62 | -2.78 | -1.46 | -0.71 | -0.58 | -0.63 | -0.60 | -0.50 | -0.78 |
| Shares Outstanding | 1.08M | 1.02M | 1.20M | 1.26M | 6.52M | 10.64M | 33.41M | 33.45M | 34.20M | 36.51M | 46.58M | 47.70M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 1.08M | 1.02M | 1.20M | 1.26M | 6.52M | 10.64M | 33.41M | 33.45M | 34.20M | 36.51M | 46.58M | 47.70M |
| EBITDA | -10.95M | -9.99M | -13.31M | -16.66M | -19.61M | -18.61M | -26.53M | -21.80M | -23.93M | -25.80M | -27.27M | -40.93M |